Journal
LIFE-BASEL
Volume 12, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/life12010081
Keywords
fibroblast growth factor receptors; FGFR fusions; next generation sequencing; first line; target therapy; FGFR inhibitors; Tyrosine kinase inhibitors; precision medicine; bemarituzumab
Categories
Ask authors/readers for more resources
Gastric cancer is the third leading cause of cancer-related death worldwide. Late diagnosis and lack of screening programs are major challenges. Novel diagnostic techniques and molecular pathways, such as the FGFR pathway, have been identified to improve survival in gastric cancer patients.
Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient's survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available